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ORIGINAL ARTICLE
BDNF val66met association with serotonin transporter
binding in healthy humans
PM Fisher1, B Ozenne1,2, C Svarer1, D Adamsen1, S Lehel3, WFC Baaré4, PS Jensen1 and GM Knudsen1
The serotonin transporter (5-HTT) is a key feature of the serotonin system, which is involved in behavior, cognition and personality and
implicated in neuropsychiatric illnesses including depression. The brain-derived neurotrophic factor (BDNF) val66met and 5-HTTLPR
polymorphisms have predicted differences in 5-HTT levels in humans but with equivocal results, possibly due to limited sample sizes.
Within the current study we evaluated these genetic predictors of 5-HTT binding with [11C]DASB positron emission tomography (PET)
in a comparatively large cohort of 144 healthy individuals. We used a latent variable model to determine genetic effects on a latent
variable (5-HTTLV), reﬂecting shared correlation across regional 5-HTT binding (amygdala, caudate, hippocampus, midbrain, neocortex,
putamen and thalamus). Our data supported a signiﬁcant BDNF val66met effect on 5-HTTLV such that met-carriers showed 2–7%
higher subcortical 5-HTT binding compared with val/val individuals (P=0.042). Our data did not support a BDNF val66met effect in
neocortex and 5-HTTLPR did not signiﬁcantly predict 5-HTTLV. We did not observe evidence for an interaction between genotypes. Our
ﬁndings indicate that met-carriers have increased subcortical 5-HTT binding. The small difference suggests limited statistical power
may explain previously reported null effects. Our ﬁnding adds to emerging evidence that BDNF val66met contributes to differences in
the human brain serotonin system, informing how variability in the 5-HTT level emerges and may represent an important molecular
mediator of BDNF val66met effects on behavior and related risk for neuropsychiatric illness.
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INTRODUCTION
Serotonin is an important neurotransmitter implicated in many
aspects of behavior and cognition.1 Dysfunction of the brain
serotonin system is thought to play a role in neuropsychiatric
illnesses including depressive and anxiety disorders.2,3 Therefore,
identifying sources of variability in serotonin signaling may help
elucidate mechanisms that drive variability in behavior and related
risk for illness. Brain-derived neurotrophic factor (BDNF) is a
signaling molecule that critically affects synaptic plasticity, axonal
growth and cell survival.4 Furthermore, compelling evidence from
animal models and human studies indicate that BDNF affects the
serotonin system.5,6 Within the human BDNF gene a common
single-nucleotide polymorphism (BDNF val66met, rs6265) has
been identiﬁed wherein the met-allele is associated with reduced
activity-dependent BDNF release.7 This polymorphism has been
associated with inter-individual variability in multiple behavioral
phenotypes including memory performance, aggression and fear
recall.7–10 The met-allele has been associated with increased
vulnerability for depression in the presence of stressful life events.11
Another recent study reported an over-representation of met/met
individuals with post-traumatic stress disorder and exaggerated
startle responses,12 consistent with an association between the
met-allele and impaired fear extinction.9 Therefore, identifying
serotonin mechanisms sensitive to BDNF val66met genotype
would elucidate its role as a potential molecular mediator of this
variant on behavior and risk for neuropsychiatric illness.
Molecular neuroimaging genetics studies using positron emis-
sion tomography (PET) have reported that compared with BDNF
val66met val/val individuals, met-carriers show decreased serotonin
1A receptor (5-HT1A) binding,
13 but see also Henningsson et al.,14
and increased serotonin 4 receptor (5-HT4) binding, a putative
marker for brain serotonin levels15 but no differences in serotonin
2A receptor binding.16 The BDNF val66met effect on serotonin
transporter (5-HTT) binding is unclear as previous studies have
reported lower binding in met-carriers but only in males14 and no
genotype differences.16,17 The 5-HTT is a key component of the
serotonin system as it is the central mechanism by which
serotonin is cleared from the extracellular space.18 However, the
relatively small sample size of these studies (N= 25–52) coupled
with the infrequency of the met-allele (~0.2 in European
populations) suggests these studies are limited in identifying a
potentially small BDNF val66met effect. Furthermore, BDNF
val66met effects may have been moderated by additional genetic
variants such as the commonly studied 5-HTTLPR polymorphism
in the 5-HTT gene (SLC6A4), which in some studies has been
shown to affect 5-HTT binding,19–21 but see also Parsey et al.22 and
Murthy et al.23 and moderate effects of BDNF val66met on brain
function24 and personality.25 Here we aimed to further character-
ize the effect of BDNF val66met on 5-HTT levels in a comparatively
large cohort of 144 healthy individuals using [11C]DASB PET.
MATERIALS AND METHODS
Participants
Data were included from the Cimbi database.26 All participants were
recruited by advertisement for different research protocols approved by
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the Ethics Committee of Copenhagen and Frederiksberg, Denmark ((KF)
01-124/04, (KF) 01-156/04, (KF) 01 2006-20, H-1-2010-085, H-1-2010-91,
H-2-2010-108, including amendments). Written informed consent was
obtained from all participants after a complete description of the
respective study. Although inclusion criteria varied slightly across studies,
(for example, some studies recruited only males or females), all participants
included here were generally healthy and without: 1) primary psychiatric
disease, 2) substance or drug abuse and 3) severe systemic or neurological
disease based on self-reported history and physical/neurological examina-
tion. Additional criteria for inclusion in this study were: (1) a [11C]DASB PET
scan before any intervention, (2) available BDNF val66met and 5-HTTLPR
genotype, (3) self-identiﬁed European ancestry and (4)⩽ 51 years old (to
limit partial volume effects and because of a clear break in the age
distribution of [11C]DASB scans between 51 and 63 years of age). [11C]DASB
PET scans were acquired between 2005 and 2012. Subgroups of individuals
with PET data presented here have been included in previous studies.27–34
Most notably, data presented here were included in previous reports of
BDNF val66met16 and 5-HTTLPR effects on 5-HTT binding.19
Genotyping
BDNF val66met genotype was determined as previously described.15 5-
HTTLPR genotype, including the A/G single-nucleotide polymorphism
(rs25531), was determined as previously described.35 BDNF val66met
genotype was in Hardy–Weinberg equilibrium (χ2 = 1.6, (degree of
freedom) df = 1, P= 0.20), whereas this test is not appropriate for 5-
HTTLPR because this was an inclusion criterion for some studies.32,33
MRI data acquisition
A high-resolution T1-weighted structural brain scan was acquired for each
participant and used for segmentation and delineation of regions of
interest. Scans were acquired on one of two magnetic resonance imaging
(MRI) scanners, a Siemens Magnetom Trio 3 T scanner or a Siemens Verio
3 T scanner (Siemens, Erlangen, Germany).
[11C]DASB PET data acquisition
PET scans were acquired on one of two PET scanners, an 18-ring GE-
Advance scanner (General Electric, Milwaukee, WI, USA) operating in three-
dimensional (3D)-acquisition mode with an approximate in-plane resolu-
tion of 6 mm or a Siemens ECAT high-resolution research tomograph
(HRRT) scanner operating in 3D-acquisition mode with an approximate in-
plane resolution of 2 mm. Following a 10- or 6-min transmission scan
(Advance and HRRT, respectively), an intravenous bolus injection of [11C]
DASB was given over 12 or 20 s (Advance and HRRT scanner) and a
dynamic 90-min emission scan was acquired over 36 frames (6 × 10 s,
3 × 20 s, 6 × 30 s, 5 × 60 s, 5 × 120 s, 8 × 300 s, 3 × 600 s). Dynamic PET
images acquired on the Advance scanner were reconstructed using ﬁltered
back projection and corrected for attenuation, dead-time and scatter using
a 6-mm Hann ﬁlter. Dynamic PET images acquired on the HRRT scanner
were reconstructed using an iterative OP-OSEM3D method with resolution
modeling (10 iterations and 16 subsets).36–38
The automatic image registration algorithm was used to determine
single-subject within PET scan motion and realignment.39 PET scans were
smoothed using a 12- or 10-mm within-frame Gaussian ﬁlter before
alignment (Advance and HRRT). We estimated rigid translation/rotation
parameters aligning each PET frame to a single PET frame with sufﬁcient
structural information using the scaled least squares cost function (frame
26: 20–25 min post injection). Non-ﬁltered PET images were resliced using
these parameters. Co-registration of high-resolution MR and PET images
was performed using automatic image registration or SPM (Advance and
HRRT) based on the mean of frames 10–26, corresponding to a ﬂow-
weighted image. Accurate co-registration was conﬁrmed by visual
inspection across all planes.
Regions were automatically delineated on the participant’s structural
MRI scan using Pvelab.40 Time-activity curves reﬂecting the mean of gray-
matter voxels within each region were determined except for the midbrain
region of interest where the mean time-activity curve across all voxels was
used. Regional binding potential estimates (BPND) were determined from
kinetic modeling of regional time-activity curves in PMOD (Zurich,
Switzerland) using the multilinear reference tissue model (MRTM/MRTM2)
with a ﬁxed k2’ estimated for each individual using a striatal high binding
region and cerebellum as the reference region.41 Bilateral regional BPND
values were calculated by computing a volume-weighted mean from the
left and the right hemisphere.
Data analysis
Statistical analyses were carried out in R v3.2.2 (https://cran.r-project.org/).
The primary outcome measures were regional BPND values for neocortex
(including occipital-, orbitofrontal-, parietal–cortex, pre/post central-,
middle/inferior frontal-, middle/inferior temporal-, superior frontal- and
superior temporal-gyrus), amygdala, caudate, hippocampus, midbrain and
thalamus. A single neocortex region was selected in part because of
previous observations of particularly high correlation between cortical
regions.27 Genotype groupings for all analyses were BDNF val66met: val/
val versus met-carriers (at least one met-allele) and 5-HTTLPR: LALA vs S’-
carriers (at least one LG or S-allele). Age, sex, PET scanner, MRI scanner,
weight-adjusted injected mass of DASB, daylight minutes on day of PET
scan and body-mass index were considered as covariates and retained as
supported by the data. All continuous variables were mean-centered and
dichtomous variables were dummy coded as 0/1.
Latent variable models were estimated using the lava package30 in R.
We modeled all regional BPND values onto a single latent variable (5-
HTTLV), reﬂecting shared correlation in BPND across regions.
27 We then
attempted to model all covariate effects through 5-HTTLV. PET and MRI
scanner effects were modeled directly on to each regional BPND estimate
because of evidence for region-speciﬁc effects, consistent with our
previous observation with a different radioligand.15 The addition of model
paths was considered iteratively, based on Wald tests of improvement in
model ﬁt with a false-discovery rate of qo0.05 (Benjamini–Hochberg
false-discovery rate-corrected) across all possible paths. This allowed us to
effectively determine the inclusion of model paths supported by the data
while controlling the rate of false-positive model paths. Overall, model ﬁt
was assessed by comparison of our model against a saturated model, root
mean square error of approximation (RMSEA) and support for additional
model paths.42 Regional BPND residuals were visually inspected for
normality. An identiﬁable model was chosen such that covariate effects
reported can be interpreted in terms of effects on thalamus BPND
(reference scale). The entire model was estimated simultaneously and P-
valueso0.05 (two-sided) were considered statistically signiﬁcant.
Corresponding univariate linear regression models were estimated for
each region. Reported percent differences in 5-HTT BPND reﬂect the BDNF
val66met parameter estimate expressed as a fraction of the intercept
parameter estimate for the corresponding linear regression model, multiplied
by 100. Unless otherwise stated, results are reported with parameter
estimates and 95% conﬁdence intervals in brackets with associated units.
Code availability
R code for latent variable model or other analyses described in the
manuscript can be made available upon request.
RESULTS
Demographic and PET scan information is detailed in Table 1.
Notably, genotype groups were well balanced across variables and
there was no association between BDNF val66met and 5-HTTLPR
genotype (χ2 = 0.02, df = 1, P= 0.90).
An initial evaluation of regional BPND indicated that they were
highly intercorrelated (Supplementary Figure 1). Consistent with
this, loadings on the single latent variable, 5-HTTLV, strongly
supported shared correlation across regions (all loadings:
Po10−12). Weight-adjusted injected DASB mass, daylight minutes
and body mass index were not signiﬁcantly associated with 5-
HTTLV and removed from the model. Additional shared inter-
regional correlations between (1) caudate and putamen, (2)
midbrain and thalamus and (3) amygdala and hippocampus were
supported by Wald tests (qo0.03). Wald tests supported an
additional direct effect of BDNF val66met on neocortex (q= 0.02).
Sex was not predictive of 5-HTTLV but Wald tests supported a
direct effect on caudate (q= 0.02). Subsequently, no additional
paths were supported by Wald tests (q40.3), consistent with good
overall model ﬁt. Fit of our ﬁnal model was less than that of a
saturated model (log-likehood ratio test: X2 = 50.9, df = 34,
P= 0.03), suggesting less than ideal model ﬁt. However, RMSEA
was within commonly accepted bounds (RMSEA= 0.058, 90%
conﬁdence interval (CI): (0.018, 0.09)) and no additional model
paths were supported (q40.3), suggesting good model ﬁt. Adding
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the most strongly (but not signiﬁcantly) supported additional path
more closely aligned model ﬁt with the saturated model (log-
likelihood ratio test: P= 0.07) without substantively affecting
genotype effects. Taken together, we retained the model
excluding this not signiﬁcantly supported path to limit the
addition of false-positive paths and conclude good but not ideal
model ﬁt.
Our ﬁnal model is depicted in Figure 1. Genetic effects in
corresponding univariate models can be found in Table 2. Within
our ﬁnal model BDNF val66met signiﬁcantly predicted 5-HTTLV
(met-carriers versus val/val: 0.085 (0.0031, 0.17), P= 0.042, units:
thalamus BPND), which signiﬁcantly captured shared correlation in
5-HTT BPND across regions. More speciﬁcally, met-carriers showed
2–7% higher 5-HTT BPND across subcortical brain areas compared
with val/val individuals (Figure 2). The BDNF val66met effect on
neocortex BPND is the sum of the direct (BDNF val66met →
neocortex BPND) and indirect (BDNF val66met → 5-HTTLV →
neocortex BPND) effects, which indicates no genotype effect on
this region (total met-carrier versus val/val neocortex effect:
− 0.004, (−0.024, 0.016), units: neocortex BPND; Figure 2). We also
observed a signiﬁcant negative effect of age on 5-HTTLV (estimate:
− 0.098 (−0.15, − 0.042), P= 0.00069, units: thalamus BPND per
decade) and a caudate-speciﬁc effect of sex (male versus female:
0.14 (0.062, 0.21), P= 0.00036, units: caudate BPND). MRI and PET
scanner effects are reported in Supplementary Table 1. We did not
ﬁnd evidence for an interaction between 5-HTTLPR and BDNF
val66met in predicting 5-HTTLV (P= 0.11).
DISCUSSION
Here we evaluated BDNF val66met effects on 5-HTT binding
within a comparatively large molecular neuroimaging data set of
144 healthy individuals using a latent variable model framework.
Our ﬁndings support that 5-HTT binding across the brain is well
described by a single latent variable (5-HTTLV), reﬂecting
signiﬁcant shared correlation across regions. BDNF val66met
signiﬁcantly predicted subcortical 5-HTT binding as evidenced
by an effect on 5-HTTLV but no effect on neocortex 5-HTT binding.
Met-carriers showed 2–7% higher subcortical 5-HTT binding
compared with val/val individuals. 5-HTTLPR did not signiﬁcantly
predict 5-HTT binding in our model nor did we observe evidence
for an interaction between genotypes. Our signiﬁcant but relatively
small group differences may explain equivocal ﬁndings from
previous studies. This ﬁnding provides additional evidence for an
effect of BDNF val66met on the adult human brain serotonin
system, which may represent a molecular mediator of its effects on
behavior, personality and risk for neuropsychiatric illness.
Previous reports of BDNF val66met effects on 5-HTT binding
have been inconsistent where one study reported decreased 5-
HTT binding in met-carriers, but only in 16 males from a cohort of
25 individuals.14 Our group and another previously reported
nonsigniﬁcant effects on 5-HTT binding in 52 and 41 individuals,
respectively.16,17 Here we report signiﬁcantly greater 5-HTT
binding in met-carriers across subcortical regions. Considering
the relatively small difference in 5-HTT binding (2–7%) that we
observed, it is quite plausible that previous studies were under-
powered to detect an effect. Notably, we observed a signiﬁcant
effect of BDNF val66met including 43 of the data sets from our
previous study (nine excluded because of age).16 Considering
evidence that the BDNF val66met met-allele is associated with
reduced trafﬁcking and activity-dependent BDNF release,7 our
Table 1. Demographic and [11C]DASB PET scan information
Total BDNF val66met 5-HTTLPR
val/val met-carrier LALA S'-carrier
N 144 92 52 (9 met/met) 42 102 (53 S'S')
Age (mean± s.d.) 26.7± 7.1 26.4± 7.2 27.0± 7.1 25.9± 5.4 27.0± 7.7
Sex (F/M) 85/59 54/38 31/21 24/18 61/41
Body mass index 23.6± 2.9 23.3± 2.7 24.3± 3.1 24.0± 3.0 23.5± 2.9
Daylight minutes 669± 219 671± 219 666± 220 632± 201 685± 225
PET scanner (A/H) 43/101 31/61 12/40 13/29 30/72
MRI scanner (T/V) 84/60 53/39 31/21 22/20 62/40
k2' (per min) 0.066± 0.013 0.065± 0.013 0.066± 0.012 0.066± 0.014 0.065± 0.012
AUCcerebellum (Bq ml
− 1) 16494± 4531 16413± 4418 16 638± 4763 16 271± 4426 16 586± 4591
[11C]DASB-injected mass (μg) 3.16± 3.09 3.18± 2.91 3.13± 3.43 2.85± 2.93 3.29± 3.16
[11C]DASB-injected dose (MBq) 552± 78 553± 72 550± 87 562± 73 548± 80
Abbreviations: μg, microgram; A, GE-Advance PET scanner; AUC, area under the curve for reference region [11C]DASB time-activity curve; BDNF, brain-derived
neurotrophic factor; F, female; M, male; MBq, mega-bequerel; MRI, magnetic resonance imaging; H, HRRT PET scanner; PET, positron emission tomography; k2’,
[11C]DASB kinetic modeling parameter; T, Trio MRI scanner; V, verio MRI scanner. No signiﬁcant group differences for either genotype, for any measure (P40.05).
Figure 1. Latent variable model. Blue hatched boxes represent
observed predictors. The green oval represents the estimate latent
variable, 5-HTTLV. Orange solid boxes represent measured regional
5-HTT BPND values. Lines denote included model paths. Although
not indicated, MRI scanner and PET scanner are modeled as
predictors of regional 5-HTT BPND. BDNF val66met val/val and 5-
HTTLPR LALA are reference groups for respective parameter
estimates. Hatched lines between regions indicate additional shared
correlation. Hatched circles indicate error estimates included.
Parameter estimates, β, for each model path indicated in respective
boxes with either 95% conﬁdence interval or P-value noted. All
regions signiﬁcantly loaded on the latent variable (all factor
loadings: Po10− 12). 5-HTT, serotonin transporter; BDNF, brain-
derived neurotrophic factor; MRI, magnetic resonance imaging; PET,
positron emission tomography.
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ﬁndings indicate these effects contribute to an increase in 5-HTT
levels as indexed by [11C]DASB PET. Linking genetic variation with
differences in neurobiology enables our ability to more compre-
hensively model neurobiology via easily acquired genetic
information. Our current ﬁndings provide a more complete
representation of how BDNF val66met shapes individual differ-
ences in serotonin signaling, which is implicated in myriad aspects
of behavior, brain function and neuropsychiatric illnesses.
We did not ﬁnd evidence for a BDNF val66met effect on
neocortex 5-HTT binding. This is reﬂected by the sum of the direct
and indirect paths between these two variables. The data-driven
addition of the direct BDNF val66met → neocortex path in our
model signiﬁcantly improved model ﬁt, indicating that the BDNF
effect on neocortex via the latent variable insufﬁciently captures
its effect on neocortex. We previously observed evidence for a
neocortex-speciﬁc effect of 5-HTTLPR on 5-HT4 binding in healthy
controls.15 Considering that 5-HTT BPND is relatively low in
neocortex, our null ﬁnding may reﬂect a type-II error stemming
from low signal-to-noise. Alternatively, evidence from non-human
primates and rodent models indicates that serotonin projec-
tions to cortex are sparse relative to subcortical projections
and evidence relatively few synapses, suggesting volume
transmission.43–45 As such, it is also possible that 5-HTT levels in
neocortex are regulated differently compared with subcortical
regions, affecting sensitivity to genetic variation. Regardless, our
ﬁndings suggest that, although there is high correlation in 5-HTT
BPND across regions, suggesting the presence of ‘global regula-
tors’, region-speciﬁc effects should also be considered.
We did not ﬁnd evidence for a 5-HTTLPR effect on 5-HTTLV,
although nominally decreased 5-HTTLV in S’-carriers is consistent
with in vitro evidence of reduced SLC6A4 transcription.46 Similar
previous molecular neuroimaging genetics studies are mixed with
some reporting reduced 5-HTT binding in S-carriers,19–21 whereas
other studies have reported no effect.22,23 Epigenetic information
was not available for these data but should be considered in
future studies as epigenetic factors such as DNA methylation in
the SLC6A4 gene could have moderated 5-HTTLPR effects on 5-
HTT binding, possibly explaining the limited correspondence
between in vitro and in vivo 5-HTTLPR effects on 5-HTT levels.
Here, S’-carriers showed particularly lower 5-HTT BPND in the
amygdala, a central brain region for processing salient environ-
mental stimuli and previously linked both to 5-HTTLPR genotype
and 5-HTT BPND (Table 2).
47–49 Thus, although it is an intriguing
possibility that 5-HTT levels mediate a 5-HTTLPR effect on
amygdala function and related behavioral phenotypes, our current
ﬁndings further suggest this effect is limited in size and therefore
would require a uniquely large multimodal neuroimaging sample.
Unsurprisingly, BPND estimates were consistently higher on the
HRRT compared with Advance scanner. The higher-resolution
HRRT limits spill-in effects of neighboring areas with low binding.
However, it is notable that the magnitude of this effect varied
across regions, which we could model within this structural
equation model framework, highlighting its strength in studies
pooling heterogeneous data. We also observed evidence for a
difference in 5-HTT BPND between MRI scanners such that
midbrain 5-HTT BPND was higher in Verio scans. Notably, only
Table 2. Genetic effects on regional [11C]DASB binding from univariate models
Region BDNF val66met 5-HTTLPR
Estimate 95% CI P PFWE Estimate 95% CI P PFWE
Amygdala 0.036 − 0.060, 0.13 0.46 1.00 − 0.102 − 0.20, − 0.0012 0.05 0.33
Caudate 0.102 0.0046, 0.20 0.04 0.24 − 0.090 − 0.19, 0.012 0.08 0.50
Hippocampus 0.016 − 0.027, 0.059 0.47 1.00 − 0.018 − 0.063, 0.028 0.44 1.00
Midbrain 0.086 − 0.0034, 0.18 0.06 0.29 0.003 − 0.091, 0.097 0.95 1.00
Neocortex − 0.004 − 0.024, 0.016 0.70 1.00 − 0.015 − 0.036, 0.0066 0.18 0.88
Putamen 0.106 − 0.0040, 0.22 0.06 0.29 − 0.043 − 0.16, 0.073 0.46 1.00
Thalamus 0.118 0.011, 0.23 0.03 0.21 − 0.009 −0.12, 0.10 0.87 1.00
Abbreviations: BDNF, brain-derived neurotrophic factor; CI, conﬁdence interval; FWE, family-wise error; MRI, magnetic resonance imaging; PET, positron
emission tomography. Effects are expressed as minor allele (met-carrier or S-carrier) relative to major allele (val/val or LL). Age, PET scanner, MRI scanner and
sex (caudate only) included as covariates in regression models. PFWE reﬂects Bonferroni–Holm correction across seven regions.
Figure 2. Representative BDNF val66met effects on thalamus and neocortex 5-HTT BPND. BDNF val66met met-carriers showed higher 5-HTT
BPND in thalamus and other subcortical regions but not neocortex (see Table 2 for model estimates). Orange dots represent 144 individual 5-
HTT BPND values, adjusted for age, MRI scanner and PET scanner. Blue lines represent group mean± 1 s.d. 5-HTT, serotonin transporter; BDNF,
brain-derived neurotrophic factor; MRI, magnetic resonance imaging; PET, positron emission tomography.
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women were scanned on this scanner, who showed nominally
higher midbrain BPND compared with the men considering only
Trio scans in a univariate framework (male versus female midbrain
BPND, Trio scans only: − 0.08 (−0.22, 0.056)), which may have
contributed to this difference. The resolution and quality of T1-
weighted high-resolution Verio and Trio scanners are comparable,
and we are therefore cautious in interpreting this observation but
encourage future studies to consider potential MRI-related effects
where relevant.
We observed a negative effect of age on 5-HTTLV, consistent
with other PET markers of the serotonin system,50–52 correspond-
ing to a 2–10% decrease in regional 5-HTT BPND per decade. In
addition, caudate 5-HTT BPND only was signiﬁcantly higher in
males compared to females. We previously reported this region-
speciﬁc effect considering only the Advance PET data included in
the current study.19,30 Remarkably, we observed a similar effect
considering only the HRRT PET data (male versus female caudate
BPND, HRRT scans only: 0.27 (0.028, 0.52), see Supplementary Table
2 for other regional estimates), providing additional evidence for
our previously reported region-speciﬁc effect of sex on caudate 5-
HTT BPND in an independent cohort.
Two recent studies have reported BDNF val66met effects on 5-
HT4 and 5-HT1A binding in healthy adults.
13,15 It is not clear
whether BDNF val66met effects stem from related or parallel
genetic effects but these receptors show notably distinct neuronal
distributions. The 5-HTT is primarily expressed on serotonin
neurons, whereas 5-HT1A is located on non-serotonin neurons
(except in raphe) and 5-HT4 is primarily expressed in striatum on
interneurons and projection medium spiny neurons.53,54 It is also
not known whether BDNF val66met-induced differences emerge
during development; however, this is plausible, given the
prominent role in development of both systems and evidence
that BDNF manipulation during development affects the serotonin
system.55–58 Although our ﬁndings diverge from a study in mice
that reported heterozygous knockout of Bdnf decreased 5-HTT
levels in hippocampus,59 we are cautious in directly comparing
such ﬁndings to single-nucleotide polymorphism effects in
humans because of similar divergent ﬁndings with other BDNF–
serotonin associations.16,60 Further, the net BDNF val66met effect
on the serotonin system is likely best described by its effect on a
broader serotonin system feature set, rather than only 5-HTT
binding. As such, multitracer PET studies wherein 5-HTT, 5-HT4, 5-
HT1A binding and other serotonin measures are acquired within
the same individuals would provide a more complete estimate of
serotonin system features, enabling a more comprehensive
assessment of how serotonin signaling is regulated by BDNF
val66met and other genetic or epigenetic mechanisms.
Our study is not without its limitations. Our cohort includes data
pooled across studies with varying inclusion criteria. Nevertheless,
all participants met a common basic criteria of general health, all
data were collected and processed in the same manner, including
the same quality-control checks throughout processing. Another
source of heterogeneity is regionally variable scanner differences.
However, BDNF val66met effects were similar when considering
only HRRT scans (BDNF val66met effect on 5-HTTLV, HRRT scans
only: 0.11, (0.0035, 0.22)), suggesting that our effect is not
confounded by scanner effects. Although we conclude a BDNF
val66met effect on 5-HTTLV and not each region independently, this
can be viewed as a sensible trade-off, given compelling evidence
for shared correlation across regions (Supplementary Figure 1). This
indicates that the alternative, a univariate test for each region, fails
to leverage shared information across regions. Consistent with this
notion, we would not ﬁnd evidence for a statistically signiﬁcant
BDNF val66met effect on any region with a univariate strategy
following reasonable multiple comparison correction (Table 2). This
emphasizes the value of modeling shared correlation in multivariate
frameworks such as latent variable models, which is highly relevant
to molecular neuroimaging where regional binding measures are
often intercorrelated and effect sizes may be small.27
In summary, our ﬁndings indicate that BDNF val66met met-
carriers show signiﬁcantly increased subcortical 5-HTT binding (2–
7% across regions) but no effect in neocortex. We replicate a
negative correlation with age and evidence that males show
higher BPND in caudate. These ﬁndings provide additional
evidence for BDNF val66met effects on the brain serotonin
system, a potential molecular mediator of its effects on behavior,
personality and related risk for neuropsychiatric illness.
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